According to a recent press release, Endologix, Inc. and TriVascular Technologies, Inc. have entered into a definitive merger agreement. The merger, in which TriVascular will survive as a wholly-owned subsidiary of Endologix, is set to close in January of 2016. The two companies will combine in a stock and cash transaction valued at approximately $211 million. The business will continue to operate its United States headquarters in Irvine, California. 
Endologix is a medical device company that develops and manufactures minimally invasive treatments for aortic disorders. According to its website, Endologix focuses on endovascular stent grafts for treatment of abdominal aortic aneurysms, a weakening of the aortic wall. Similarly, TriVascular is a medical device company that provides solutions for endovascular aortic repair that focuses on endovascular grafts.
Nasdaq GlobeNewswire states that the merger will form one of the most innovative companies in treating endovascular abdominal aortic aneurysms. In the press release, both TriVascular President and Chief Operating Officer, Christopher G. Chavez, and current and future Chairman and Chief Executive Officer of Endologix, Inc., John McDermott, emphasieze that the merger will increase accessibility to the companies’ minimally invasive technologies. Additionally, Mr. McDermott stated:
This merger enhances the near and long-term growth potential of our business by bringing together two of the most innovative companies in the field of endovascular abdominal aortic aneurysm (“AAA”) treatment. We believe the combined company will be uniquely positioned to provide physicians with . . . complementary products to treat a wide range of patient anatomies.
As noted on its website, Endologix presently offers several products: the AFX EndoVascular AAA System, Nellix EndoVascular Aneurysm Sealing System, and the Intuitrak Powerlink System. Of the three devices, only the AFX is presently listed by Endologix as being available for use in the United States. TriVascular’s website offers a single product: the Ovation Prime solution for EndoVascular Aortic Repair, which, TriVascular notes, is already FDA approved. In addition to the companies’ existing products, John McDermott states that “the newly combined company will have a deep pipeline of new devices including AFX2 and the Ovation IX system that are both planned for market introduction by the first quarter of 2016.”
